Literature DB >> 24115004

Inherently poor survival of elderly patients with nasopharyngeal carcinoma.

Ye Zhang1, Jun-Lin Yi1, Xiao-Dong Huang1, Guo-Zhen Xu1, Jian-Ping Xiao1, Su-Yan Li1, Jing-Wei Luo1, Shi-Ping Zhang1, Kai Wang1, Yuan Qu1, Li Gao1.   

Abstract

BACKGROUND: The purpose of this study was to determine the features of the elderly patient with nasopharyngeal carcinoma (NPC).
METHODS: The medical records of 212 patients with NPC, aged ≥65 years, and receiving radiotherapy were retrospectively reviewed. Comorbidity was rated using the Charlson Comorbidity Index (CCI).
RESULTS: Twenty-four patients (11.3%) scored ≥3 and 188 patients (88.7%) scored <3 rated by CCI. The median actuarial irradiated dose of the nasopharynx was 72 Gy (range, 20-94 Gy) with 87.3% patients receiving >70 Gy. One hundred fifty-four patients had stage III/IV disease. The actuarial local control, cancer-specific survival (CSS), and overall survival (OS) rates at 5 years were 68.8%, 63.5%, and 47.0%, respectively. On multivariate analysis, stage (hazard ratio [HR], 1.489; 95% confidence interval [CI], 1.168-1.897; p = .001), the technique of radiotherapy (HR, 0.674; 95% CI, 0.476-0.953; p = .025), and anemia (HR, 3.081; 95% CI, 1.624-5.845; p = .001) were independent prognostic factors.
CONCLUSION: The elderly patients with NPC may inherently predict poor outcomes.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  comorbidity; elderly; nasopharyngeal carcinoma; prognosis; radiotherapy

Mesh:

Year:  2015        PMID: 24115004     DOI: 10.1002/hed.23497

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  7 in total

1.  Combined radiotherapy and chemotherapy versus radiotherapy alone in elderly patients with nasopharyngeal carcinoma: A SEER population-based study.

Authors:  Yan Lu; Jianfeng Hua; Fengqin Yan; Chuner Jiang; Yongfeng Piao; Zhimin Ye; Zhenfu Fu; Haitao Jiang; Fangzheng Wang; Yangming Jiang
Journal:  Medicine (Baltimore)       Date:  2021-07-23       Impact factor: 1.817

2.  Comparison of intensity-modulated radiation therapy alone vs. intensity-modulated radiation therapy combined with chemotherapy in elderly nasopharyngeal carcinoma patients (aged >65 years).

Authors:  Jing-Lin Mi; Yi-Liang Meng; Hong-Liang Wu; Yi-Lin Cao; Bin Zhang; Yu-Fei Pan; Yuan-Yuan Zhou; Jin-Fang Fan; Shu-Fang Liao; Xiao-Li Qin; Da-Cheng Yao; Wei Jiang
Journal:  Strahlenther Onkol       Date:  2019-11-20       Impact factor: 3.621

3.  Prognostic value of nutritional risk screening 2002 scale in nasopharyngeal carcinoma: A large-scale cohort study.

Authors:  Hao Peng; Bin-Bin Chen; Ling-Long Tang; Lei Chen; Wen-Fei Li; Yuan Zhang; Yan-Ping Mao; Ying Sun; Li-Zhi Liu; Li Tian; Ying Guo; Jun Ma
Journal:  Cancer Sci       Date:  2018-05-18       Impact factor: 6.716

4.  The Characteristics and Survival Outcomes in Patients Aged 70 Years and Older with Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era.

Authors:  Ya-Nan Jin; Wang-Jian Zhang; Xiu-Yu Cai; Mei-Su Li; Wayne R Lawrence; Si-Yang Wang; Dong-Mei Mai; Yu-Yun Du; Dong-Hua Luo; Hao-Yuan Mo
Journal:  Cancer Res Treat       Date:  2018-02-06       Impact factor: 4.679

Review 5.  Management of Nasopharyngeal Carcinoma in Elderly Patients.

Authors:  Wing Lok Chan; James Chung Hang Chow; Zhi-Yuan Xu; Jishi Li; Wing Tung Gobby Kwong; Wai Tong Ng; Anne W M Lee
Journal:  Front Oncol       Date:  2022-02-01       Impact factor: 6.244

6.  Selection and validation of chemotherapy beneficiaries among elderly nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiation therapy (IMRT): a large real-world study.

Authors:  Yan-Ling Wu; Kai-Bin Yang; Ying Huang; Jing-Rong Shi; Qing-Shui He; Lei Chen; Wen-Fei Li; Xiao-Dan Huang; Li Lin; Yu-Pei Chen; Yan-Ping Mao; Ling-Long Tang; Jun Ma
Journal:  Radiat Oncol       Date:  2022-08-08       Impact factor: 4.309

Review 7.  Age Is Not a Limiting Factor in Interventional Radiotherapy (Brachytherapy) for Patients with Localized Cancer.

Authors:  Valentina Lancellotta; György Kovács; Luca Tagliaferri; Elisabetta Perrucci; Giuseppe Colloca; Vincenzo Valentini; Cynthia Aristei
Journal:  Biomed Res Int       Date:  2018-01-21       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.